| abstract |
As compared with the current oral sustained-release preparationncontaining tamsulosin hydrochloride which have been suppliednto the medical setting at present, it is needed to provide ansustained-release pharmaceutical composition in which thenefficacy is equivalent or even better, adverse events such asnadverse reactions (e.g., postural hypotension) are reduced,ndose can be increased and, if desired, ingestion of food isnnot limited in the dosage and it is also needed to provide anmethod for administration of tamsulosin hydrochloride in whichnthe adverse reactions accompanied by therapy or prevention onnthe basis of an α 1 receptor blocking action are reduced. Ansustained-release pharmaceutical composition, characterizednin that, there are contained tamsulosin or a pharmaceuticallynacceptable salt thereof and a carrier for a sustained-releasenpharmaceutical composition and the ratio (C min /C max ratio) ofnthe plasma tamsulosin concentration at 24 hours after thenadministration of the preparation per os (C min ) to the maximumnplasma tamsulosin concentration after the administration (C max )nis about 0.4 or more. |